Arthritis Program

Arthritis Program_Eupraxia PharmaceuticalsArthritis is one of the world’s most prevalent diseases. The Centers for Disease Control and Prevention (CDC) estimates roughly one in five Americans have some form of arthritis or joint pain. Our lead product candidate, EP-104IAR pairs our sustained release technology with a potent and widely-used anti-inflammatory (fluticasone propionate) with the goal of providing months of pain relief for patients with osteoarthritis, a degenerative joint disease.

Our injectable compound is designed to remain within the affected joint and reduce access to the bloodstream, with the aim of reducing the potential for widespread side effects.